Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial

 
• By Joseph Haas
Immune checkpoint inhibitor
Kineta resumes enrolling a trial for what it hopes will be a novel class of checkpoint inhibitors • Source: Shutterstock

More from Clinical Trials

More from R&D